Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	22.39	-197.88	-528.63	-652.17	-746.35
Depreciation & Amortization	1.56	1.8	1.78	1.55	1.49
Other Amortization	2.5	1.56	0.3	0.46	0.96
Loss (Gain) From Sale of Assets	-	-	0.12	-	-
Stock-Based Compensation	104	114.13	105.95	91.09	70.67
Other Operating Activities	-	10.89	26	61.09	203.63
Change in Accounts Receivable	-101.28	-58.48	-198.72	2.38	-10.1
Change in Inventory	-15.27	-10.76	-60.65	-69.4	-16.32
Change in Accounts Payable	18.22	1.09	0.17	18.69	10.49
Change in Other Net Operating Assets	13.21	49.79	58.94	32.57	-77.59
Operating Cash Flow	45.33	-87.87	-594.74	-513.75	-563.13
Capital Expenditures	-0.31	-0.4	-0.77	-1.52	-1.1
Sale of Property, Plant & Equipment	-	-	0.1	-	-
Investment in Securities	-	-	-	61.42	248.72
Investing Cash Flow	-0.31	-0.4	-0.67	59.89	247.62
Long-Term Debt Issued	-	365.45	-	-	-
Net Debt Issued (Repaid)	-	365.45	-	-	-
Issuance of Common Stock	8.9	18.83	461.04	405.84	398.02
Repurchase of Common Stock	-0.01	-0.06	-11.04	-5.68	-1.79
Other Financing Activities	-	-234.98	-55.5	-34.5	-4
Financing Cash Flow	8.88	149.24	394.5	365.66	392.24
Foreign Exchange Rate Adjustments	1.25	-0.66	0.14	-0.49	-2.02
Net Cash Flow	55.15	60.31	-200.78	-88.68	74.71
Free Cash Flow	45.01	-88.27	-595.51	-515.27	-564.23
Free Cash Flow Margin	4.48%	-11.30%	-150.16%	-683.18%	-847.66%
Free Cash Flow Per Share	0.35	-0.71	-5.02	-4.86	-6.68
Cash Interest Paid	41.23	29.37	3.29	5	10.27
Cash Income Tax Paid	1.63	1.65	-1.76	4.92	0.05
Levered Free Cash Flow	-15.46	-35.7	-404.84	-304.6	-351.61
Unlevered Free Cash Flow	9.74	-12.01	-386.65	-284.66	-344.3
Change in Working Capital	-85.12	-18.36	-200.25	-15.76	-93.52

Updated Feb 24, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q